Table 1 Demographic and clinical features of 64 patients from the Virahep-C study
| n = 64 | Sustained virological response | ||
| Non-responders | Responders | ||
| (n = 34) | (n = 30) | ||
| Age (years) | |||
| Mean (SD) | 48.1 (8.4) | 48.1 (9.4) | 48.1 (7.3) |
| Median (25th, 75th) | 48 (44.0, 53.0) | 48 (45.0, 54.0) | 48 (43.0, 50.0) |
| Race | |||
| African–American | 34 (53.1%) | 19 (55.9%) | 15 (50.0%) |
| Caucasian–American | 30 (46.9%) | 15 (44.1%) | 15 (50.0%) |
| Gender | |||
| Male | 41 (64.1%) | 26 (76.5%) | 15 (36.6%) |
| Female | 23 (35.9%) | 8 (34.8%) | 15 (65.2%) |
| Genotype | |||
| 1a | 34 (53.1%) | 19 (55.9%) | 15 (50.0%) |
| 1b | 24 (37.5%) | 15 (44.1%) 0 (0%) | 9 (5.3%) |
| Other | 6 (9.4%) | 6 (0.2%) | |
| 1 | 3 | 3 | |
| 1a/b | 2 | 2 | |
| Indeterminate | 1 | 1 | |
| Viral level, IU/ml (log10) | |||
| Mean (SD) | 6.3 (0.7) | 6.4 (0.7) | 6.1 (0.6) |
| Median (25th, 75th) | 6.4 (5.7, 6.8) | 6.5 (6.2, 6.9) | 6.2 (5.6, 6.5) |
| Alanine aminotransferase (IU/l) | |||
| Mean (SD) | 84.8 (77.3) | 83.2 (57.2) | 86.6 (96.3) |
| Median (25th, 75th) | 60.0 (41.5, 99.5) | 65.5 (50.0, 105.0) | 53.0 (38.0, 98.0) |
| Total HAI inflammation | |||
| Mean (SD) | 8.6 (2.9) | 8.8 (2.8) | 8.3 (3.1) |
| Median (25th, 75th) | 8.0 (6.5, 11.0) | 8.0 (7.0,11.0) | 8.0 (6.0, 11.0) |
| Ishak fibrosis score | |||
| 0 | 12 (18.8%) | 4 (11.8%) | 8 (26.7%) |
| 1, 2 | 29 (45.3%) | 15 (44.1%) | 14 (46.7%) |
| 3, 4 | 21 (32.8%) | 13 (38.2%) | 8 (26.7%) |
| 5, 6 | 2 (3.1%) | 2 (5.9%) | 0 (0.0%) |
| HOMA | |||
| ⩽2 | 30 (46.9%) | 13 (38.2%) | 17 (56.7%) |
| >2 | 25 (39.1%) | 15 (44.1%) | 10 (33.3%) |
| Missing | 9 (14.1%) | 6 (17.7%) | 3 (10.0%) |
| 28 day response | |||
| Poor | 37 (57.8%) | 26 (76.5%) | 11 (29.7%) |
| Intermediate | 10 (15.6%) | 3 (8.8%) | 7 (23.3%) |
| Marked | 16 (25.0%) | 4 (11.8%) | 12 (40.0%) |
| Rebound >1.4 | 1 (1.6%) | 1 (2.9%) | 0 (0.0%) |
| Early virological response (week 12 response) | |||
| Non-responder | 19 (29.7%) | 18 (52.9%) | 1 (3.33%) |
| Responder | 45 (70.3%) | 16 (47.1%) | 29 (96.7%) |
-
At 28 days poor response was defined as </ = 1 log decrease, intermediate 1–3.5 log decrease, marked >3.5 log decrease in viral level. Early virological response was defined as RNA negativity at 12 weeks of therapy. Sustained virological response was defined as RNA negativity at 24 weeks after cessation of therapy.
-
HAI, histological activity index; HOMA, homeostasis model assessement.
